arrow
J

Javier Díaz de Terán

instituto de investigación sanitaria idipaz
H指数:13
被引数:708

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term atogepant for treatment-resistant migraine in real-world clinical practice: 12-month results (gema project)

长期阿托 gepant 用于治疗抵抗性偏头痛的真实世界临床实践:12个月结果(gema项目)

2026-09-150
OAAI
Evaluation of the effectiveness and safety of anti-CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO-CGRP study

评估抗CGRP单克隆抗体在偏头痛和自身免疫性疾病患者中的有效性与安全性:IMMUNO-CGRP研究

IF0
2026-04-010
OAAI
Predictors of Response to Occipital Nerve Stimulation in Patients with Refractory Chronic Cluster Headache: Protocol for a Prospective Observational Study

对难治性慢性丛集性头痛患者枕神经刺激反应的预测因子:一项前瞻性观察研究的方案

2026-02-270
OAAI
Development and validation of a patient-reported-experience measure to ascertain treatment satisfaction in migraine: the MISAT-Q questionnaire

开发和验证一种患者报告体验量表以确定偏头痛治疗满意度:MISAT-Q问卷

2025-12-150
PRE
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response

阿托格匹兰坦在抗CGRP单克隆抗体治疗失败的偏头痛患者中的应用:一项关于疗效、安全性、持续性和应答预测因子的多中心真实世界研究

2025-11-280
OAAI
OnabotulinumtoxinA Is an Effective Treatment for Reducing the Interictal Burden in Patients with Chronic Migraine: A Prospective Observational Study

奥马布毒素A是减少慢性偏头痛患者间期负担的有效治疗方法:一项前瞻性观察研究

2025-09-270
OAAI
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
2024-05-2210
PRE
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
2022-02-1552
OA
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
2021-07-1729
OAAI